

APPOINTMENT OF CHIEF OPERATING OFFICER

Highlights:

- *Osteopore's current Chief Technology Officer, Dr Lim Jing, has been appointed Chief Operating Officer to lead overall business operations and drive growth.*
- *The promotion forms part of Osteopore's internal development strategy to improve efficiency and support business growth and expansion, as it breaks into new markets.*
- *Dr Lim Jing will also continue in his role as Osteopore's Chief Technology Officer, in conjunction with the newly appointed role of Chief Operating Officer.*
- *Dr Lim Jing was recently selected as one of the 'In Vivo 30 Rising Leaders for 2022', an award highlighting entrepreneurs and innovators who represent the next wave of creativity in health care.*

28 April 2022: Osteopore Limited (ASX: OSX) ("Osteopore" or the "Company"), an Australian and Singapore based global leader in the manufacture of innovative regenerative implants at commercial scale, is pleased to announce its Chief Technology Officer (CTO), Dr Lim Jing, has been appointed as the Company's Chief Operating Officer (COO), effective 1 May 2022.

As Chief Operations Officer, Dr Lim Jing will be responsible for overseeing the daily business and administrative operations, assessing and enhancing the efficiency of internal and external operational processes, and collaborating with management and other stakeholders to identify initiatives to increase the value of the company.

With over a decade of experience in tissue engineering research, and a deep understanding of the Company's novel technology, Dr Lim Jing will also continue his role as Osteopore's Chief Technology Officer - in conjunction with the newly appointed role of Chief Operating Officer.

Given the significant business transformation program now being implemented at Osteopore, these two executive roles will be pivotal to the ongoing success of the company. Under this structure, Dr Lim Jing's operational scope will expand to allow for the increased utilisation of the Company's tissue regeneration technology across new applications, and accelerate the development of next generation implants to access multiple billion-dollar markets.

Furthermore, Dr Jing has been selected as one of the 'In Vivo 30 Rising Leaders for 2022', a global listing of people who are making waves and challenging traditional structures across the biopharma and MedTech sectors. He was selected due to a strong track record of commercialising Osteopore's breakthrough products, and his success in achieving regulatory approvals globally and across the APAC region.

Osteopore CEO, Goh Khoo Seng said, “Over the period that I have worked with Dr Lim, he has demonstrated outstanding technical expertise, strong leadership and a dedication to Osteopore's commercial vision. He has also been instrumental in improving our underlying technology and manufacturing processes. This new role will be critical in executing additional collaborative partnerships, gaining further regulatory clearances, and launching complementary products for additional bone regeneration applications.”

This announcement has been approved for release by the Board of Osteopore.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

+65 9011 7009

Mark_Leong@osteopore.com

About Osteopore Limited

Osteopore Limited is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material. Osteopore's patent-protected scaffolds are made from proprietary polymer formulations, that naturally dissolve over time to leave only natural, healthy bone tissue, significantly reducing postsurgery complications commonly associated with permanent bone implants.

About Dr Lim Jing

Dr. Lim holds a PhD from Nanyang Technological University, Singapore. Prior to joining Osteopore, Dr. Lim conducted research on biomaterials for tissue engineering and regenerative medicine, and developed material fabrication platforms. Dr. Lim published 14 articles in internationally peer-reviewed journals in that time. Dr. Lim joined Osteopore in November 2014, and has led Osteopore to important regulatory and quality milestones. In addition, Dr. Lim led the expansion of product and therapy portfolio, and contributed to the improvement in manufacturing efficiency.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are, or may be, forward-looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results may differ materially from those expressed or implied by these forward-looking statements depending on various factors.